Sangamo Therapeutics
| Company type | Public |
|---|---|
| Nasdaq: SGMO Russell 2000 Index component | |
| Industry | Biotechnology |
| Founded | 1995 |
| Headquarters | Brisbane, California, US |
Key people | Sandy Macrae (CEO) |
| Revenue | $111.3 million (2022) |
| -$201.281 million (2022) | |
| $192.3 million (2022) | |
| Total assets | $562.5 million (2022) |
| Total equity | $294.958 million (2022) |
Number of employees | 354 |
| Website | sangamo |
| Footnotes / references | |
Sangamo Therapeutics, Inc. (formerly Sangamo Biosciences, Inc.) is an American biotechnology company based in Brisbane, California, that develops cell and gene therapies for severe genetic diseases.